STAMFORD, Conn. (AP) _ Cara Therapeutics Inc. (CARA) on Tuesday reported a loss of $20.7 million in its fourth quarter.
The Stamford, Connecticut-based company said it had a loss of 52 cents per share.
The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 59 cents per share.
The biotechnology company posted revenue of $5.5 million in the period, which also beat Street forecasts. Five analysts surveyed by Zacks expected $3.3 million.
For the year, the company reported that its loss widened to $74 million, or $2.06 per share. Revenue was reported as $13.5 million.
Cara shares have risen 34 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $17.43, an increase of 21 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CARA at https://www.zacks.com/ap/CARA